BridgeBio Pharma BBIO Reportable Segment — Income Tax Expense (Benefit)

Similar metrics at other companies

ROIVReportable Segment — Income tax expense (benefit)

$98.35M+99.4%

LOGIReportable Segment — Income Tax Expense (Benefit)

$6.39M—

KRYSReportable Segment — Income Tax Expense (Benefit)

$5.51M-29.9%

SOReportable Segment — Income taxes (benefit)

$129M+16.2%

RMBSReportable — Income Tax Expense Benefit

$8.77M+19.8%

AKAMReportable Segment — Benefit (provision) for income taxes

$15.68M-68.8%

Questions, answered.

What is BridgeBio Pharma's reportable segment — income tax expense (benefit)?

BridgeBio Pharma (BBIO) reported reportable segment — income tax expense (benefit) of -$1.55M in Q3 2025.

What does reportable segment — income tax expense (benefit) mean?

The total amount of tax the company owes or is credited for during the reporting period.

How do you interpret reportable segment — income tax expense (benefit)?

A tax benefit can improve net income, while a high tax expense reduces it; the interpretation depends on the company's overall tax strategy.

How does reportable segment — income tax expense (benefit) compare across companies?

Standard accounting line item; varies significantly based on jurisdiction and profitability.